WiseApp for Spanish Speakers Living With HIV

HIV Infections Clinical Trial

Official title:

WiseApp for Spanish-Speaking Latino Persons Living With HIV (PLWH) in the United States (US) and the Dominican Republic (DR)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05398185
• Other study ID #: AAAT8632
• Secondary ID: 1R18HS028523-01
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2023
• Est. completion date: January 2027

Study information

• Verified date: May 2024
• Source: Columbia University
• Contact: Rebecca Schnall, PhD, MPH
• Phone: 212-342-6886
• Email: rb897[@]columbia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to conduct a 12-month randomized controlled trial to adapt the mobile app, WiseApp, and a smart pill dispenser for Spanish-speaking people living with HIV (PLWH) in the New York City (NYC) area and La Romana, Dominican Republic (DR). The study will assess the efficacy and sustainability of WiseApp as well as identify barriers with its widespread use among Spanish speakers. With disproportionately high rates of HIV in the New York City area and the Dominican Republic, this project seeks to identify distinct contextual factors related to Spanish speaking people living with HIV and increase the likelihood of engagement with technology and improvements in clinical outcomes.

Description:

While efforts have been made, deficits remain in antiretroviral therapy (ART) adherence and viral suppression among PLWH. There are gaps in HIV treatment success that are particularly present in racial and ethnic minority populations, especially among Latinos in the Northeast United States (US) and the Caribbean. The progression and premature deaths among PLWH have been attributed to insufficient engagement in medical care and adherence to HIV treatments. Access and adherence to ART are important to therapeutic success and help determine long-term health outcomes in PLWH. The investigators studied racial/ethnic minorities and their providers to identify the impact a mobile app can have to improve health outcomes. The Agency for Healthcare Research and Quality (AHRQ) helped create this app and integrated it with a smart pill box (CleverCap) which allows PLWH to monitor their medication adherence. The tool, WiseApp, is a better method than other ART adherence methods because the app is linked to the smart pill box and is currently being evaluated in random-control trials (RCT) in New York City. There is also a need to develop and test self-management interventions for Spanish speaking Latino PLWH because they are the largest and fastest growing ethnic minority group in the US and are disproportionately affected by HIV. The investigators suggest the transfer of WiseApp to Latinos in the US and the DR by translating it to Spanish and making it culturally accessible. The project will use health information technology to facilitate the collection of medication adherence, quality of life, and symptom burden data.

This study aims to adapt WiseApp for Spanish speaking PLWH and conduct RCT to assess the app's efficacy and sustainability. The study will identify barriers and facilitators to the widespread use of the app and builds on the strong linkage between Columbia University and Clínica de Familia in the DR. This project is also enhanced by utilizing the strong presence of Latinos in the Washington Heights neighborhood of NYC, the disproportionately high rates of HIV in the DR, and patterns of movement of people between NYC and the DR. Additionally, the study focuses on AHRQ priority populations such as chronically ill, inner-city, low-income, and racial/ethnic minority persons.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 248
• Est. completion date: January 2027
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to speak, read, and write in Spanish;

• Aged =18 years;

• Willing to participate in any assigned arm of the intervention;

• Have an HIV-1 RNA level >50 copies/mL;

• Own a smartphone; and

• Ability and willingness to provide informed consent for study participation and consent for access to medical records.

Exclusion Criteria:

• Reside in a nursing home, prison, and/or receiving in-patient psychiatric care at time of enrollment;

• Terminal illness with life expectancy <6 months;

• Planning to move out of the area in the next 12 months;

• A cognitive state minimum score measured by the Mini-Mental State Examination (MMSE) to ensure participants are oriented to time and place.

• Spouses/partners may not enroll in this study. The study will be limited to only 1 person from the same family/domestic household.

Related Conditions & MeSH terms

• Acquired Immune Deficiency Syndrome
• Acquired Immunodeficiency Syndrome
• HIV Infections
• Immunologic Deficiency Syndromes
• Sexually Transmitted Diseases
• Sexually Transmitted Diseases, Viral
• Virus Diseases

Intervention

Behavioral:
• WiseApp
The Intervention group will receive the WiseApp that delivers medication adherence reminders

Locations

Country	Name	City	State
Dominican Republic	Clinica de Familia La Romana	La Romana
United States	Columbia University Irving Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	Clínica de Familia La Romana, Dominican Republic

Countries where clinical trial is conducted

United States,  Dominican Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in self-reported ART adherence	Self-reported ART adherence will be measured using a 3-item scale with responses transformed to a linear scale of 0-100 with zero indicating lowest adherence and 100 indicating highest adherence. Summary scales will be calculated as the mean of the three scale items.	Baseline, 3 month follow up, 6 month follow up, and 12 month follow up
Secondary	Change in cluster of differentiation 4 (CD4) Count	Using blood samples obtained during study visits, CD4 count will be used to assess ART adherence.	Baseline, 3 month follow up, and 6 month follow up
Secondary	Change in Viral Load	Using blood samples obtained during study visits, viral load levels will be used to assess ART adherence.	Baseline, 3 month follow up, 6 month follow up, and 12 month follow up
Secondary	Change In Participant's Self-reported Health-related Quality of Life Score	Health-related quality of life will be measured with the Patient-Reported Outcomes Measurement Information System® (PROMIS)-29 measure, which measures 7 domains of health-related quality of life with 4 questions in each section pertaining to how that participant's health influences their life. In general, each question has five response options ranging in values from 1-5. To find the total raw score for this form with all the questions answered, the values from the responses of each question are summed. Raw scores are then translated into a T-score for each participant, which rescales the raw score into a standardized T-score with a mean of 50 and standard deviation (SD) of 10. Consequently, a person with a T-score of 40 would be one SD below the mean.	Baseline and 12 month follow up